AMAM News

The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL) priced at the midpoint to raise $425 million at a $4.7 billion market cap. The company is using proprietary genetic and...read more

Ambrx Biopharma, a Phase 2/3 oncology biotech developing engineered antibody-drug conjugates, raised $126 million by offering 7 million ADSs at $18, within the range of $17 to $19. Ambrx Biopharma is developing a novel class of engineered precision biologics using a proprietary genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic...read more

Ambrx Biopharma, a Phase 2/3 oncology biotech developing engineered antibody-drug conjugates, announced terms for its IPO on Monday. The La Jolla, CA-based company plans to raise $126 million by offering 7 million ADSs at a price range of $17 to $19. At the midpoint of the proposed range, Ambrx Biopharma would command a fully diluted market value of $725 million. Ambrx...read more

Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise $425 million at a $4.7 billion market cap. The company is using proprietary genetic and epigenetic reprogramming to develop T...read more